Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Maintenance Post-Allo HCT for High Risk MM
NCT02440464Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2015
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in multiple myeloma (MM), sponsored by National Heart, Lung, and Blood Institute. Started Aug 2015; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02440464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440464.